ArticleFrontiers in oncology2021
Integrative Analysis of the Expression of SIGLEC Family Members in Lung Adenocarcinoma via Data Mining.
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- Deficient extravillous trophoblast invasion caused by impaired sialylation-Siglec-7 interaction contributes to recurrent pregnancy loss.Cell death & disease · 2026Article
- Machine learning-based determination of sex-related bladder cancer biomarkers.Frontiers in bioinformatics · 2026Article
- Association of FANCD2, TFPI, and CD33 genes with prognosis of lung adenocarcinoma: a bioinformatics study.Discover oncology · 2025Article
- Topohistology of dendritic cells and macrophages in the distal and proximal nodes along the lymph flow from the lung.Journal of anatomy · 2025Article
- Tumor-infiltrating myeloid cells; mechanisms, functional significance, and targeting in cancer therapy.Cellular oncology (Dordrecht, Netherlands) · 2025Review
- Development of a Novel Anti-Siglec-15 Antibody for Tumor Immunotherapy.ImmunoTargets and therapy · 2025Article
- Elevated Siglec-7 expression correlates with adverse clinicopathological, immunological, and therapeutic response signatures in breast cancer patients.Frontiers in immunology · 2025Article
- Plasma extracellular vesicles proteomics in meningioma patients.Translational oncology · 2024Article
- Analysis ofHeliyon · 2024Article
- Characterization of genomic instability-related genes predicts survival and therapeutic response in lung adenocarcinoma.BMC cancer · 2023Article
- Recent progress in targeting the sialylated glycan-SIGLEC axis in cancer immunotherapy.Cancer biology & medicine · 2023Review
- Forkhead box L2 is a target of miR-133b and plays an important role in the pathogenesis of non-small cell lung cancer.Cancer medicine · 2023Article
- Effect of Maternal Body Mass Index on the Transcriptomic Network of Human First-Trimester Chorionic Villi.Reproductive sciences (Thousand Oaks, Calif.) · 2023Article
- Siglec-15 Regulates the Inflammatory Response and Polarization of Tumor-Associated Macrophages in Pancreatic Cancer by Inhibiting the cGAS-STING Signaling Pathway.Oxidative medicine and cellular longevity · 2022Article
- System-wide identification of myeloid markers of TB disease and HIV-induced reactivation in the macaque model of Mtb infection and Mtb/SIV co-infection.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.